Indications
Vyndaqel is indicated for the treatment of transthyretin amyloidosis in adult patients with stage-1 symptomatic polyneuropathy to delay peripheral neurologic impairment.
Composition
- Active substance
- tafamidis
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Vyndaqel
- Active substance
- tafamidis
- ATC code
- N07XX08
- Group
- Nervous system
- Therapeutic area
- Amyloidosis
- Marketing authorisation holder
- Pfizer Europe MA EEIG
- Status
- Authorised
- EU authorisation
- 16 Nov 2011